'Fue empezar a leer y ya no poder abandonar el libro, que lo tiene todo.' - Bill Gates
'Estremecedor... Se lee como un thriller... Carreyrou cuenta [la historia de Theranos] a la perfección.' - The New York Times Book Review
'El compromiso de Carreyrou por desentrañar el fraude de Theranos sirvió, literalmente, para salvar vidas.' - Booklist
En 2014, Elizabeth Holmes, fundadora de Theranos, parecía destinada a tomar el relevo de Steve Jobs. Su empresa, que llegó a valorarse en nueve mil millones de dólares, prometía revolucionar la industria médica a partir de una gota de sangre, lo único que, junto a la máquina de Theranos, haría falta para poner la sanidad al alcance de todos. El problema era uno solo: la tecnología no funcionaba. Cuando John Carreyrou, periodista del Wall Street Journal, empezó a hacer preguntas, lo que recibió fueron amenazas judiciales. Aun así, el diario publicó el primero de numerosos artículos sobre Theranos. A principios de 2017, el valor de la compañía había llegado a cero. He aquí la historia completa del asombroso ascenso y caída de una empresa multimillonaria, contada por el periodista que destapó el escándalo e investigó los hechos hasta el final.
Un homenaje y una honra para el periodismo en tiempos de posverdad.
Der beispiellose Absturz eines Start-up-Wunderkinds.
Elizabeth Holmes, Gründerin und CEO von Theranos, galt schnell als der weibliche Steve Jobs. Die Firma der 19-jährigen Blondine versprach, die Medizinindustrie mit einer Technologie zu revolutionieren, die Bluttests vereinfachen und Therapien gezielt steuern würde - eine Riesenhoffnung für Millionen von Menschen. Larry Ellison, Rupert Murdoch und andere Investoren steckten Unsummen in das Start-up, bis es mit neun Milliarden Dollar am Markt kapitalisiert war.
Es gab nur ein einziges Problem: Die Technologie hinter den schicken Apparaturen hat nie funktioniert. Pulitzer-Preisträger John Carreyrou erzählt die packende Geschichte dieses Betrugs und seiner Enthüllung.
The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.
'Crime thriller authors have nothing on Carreyrou's exquisite sense of suspenseful pacing and multifaceted character development in this riveting, read-in-one-sitting tour de force....Carreyrou's commitment to unraveling Holmes' crimes was literally of life-saving value.' -Booklist
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.
A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
A New York Times Bestseller
Shortlisted for the Financial Times/McKinsey Business Book of the Year Award
The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.
In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
Now to be adapted into a film, with Jennifer Lawrence to star.
'Chilling . . . Reads like a West Coast version of All the President's Men.' New York Times Book Review
